Posted on

FDA Approves Drug Trio for UTI, Intra-abdominal Infection

Posted on

The US Food and Drug Administration (FDA) has approved the antibacterial drug trio imipenem, cilastatin, and relebactam (Recarbrio, Merck) for complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in adults for whom “limited or no treatment options are available.”

Recarbrio provides an important addition to our toolkit in the ongoing fight against infections caused by certain Gram-negative pathogens,” Keith Kaye, MD, professor of medicine and director of research for the division of infectious diseases, University of Michigan Heath System, and a principal investigator in the clinical program, said in a company news release.

Recarbrio offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options,” he added.

The three-drug combination is given by injection that contains previously approved antibiotics — imipenem-cilastatin — and a new beta-lactamase inhibitor, relebactam.

The approval follows consideration of efficacy and safety findings for imipenem-cilastatin from in vitro studies and animal models of infection for relebactam. The safety of the drug trio was studied in one trial of 298 adults with cUTI (99 treated with drug combination) and one trial of 347 adults with cIAI (117 treated with drug combination). Participants received the study drug at the proposed dose, according to an FDA news release.

The most frequently seen adverse events in patients who received imipenem/cilastatin/relebactam were diarrhea, nausea, headache, fever, and elevated liver enzymes.

Patients taking ganciclovir should not take imipenem/cilastatin/relebactamunless the benefits outweigh the risks because there have been reports of generalized seizures. The drug trio should also not be used in those taking valproic acid or divalproex sodium for seizure management because a reduced valproic acid level may result in seizures.

The drug trio is intended for cUTI, including pyelonephritis, resulting from susceptible Gram-negative microorganisms Enterobacter cloacaeEscherichia coliKlebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

The drug combination is also intended for cIAI resulting from susceptible Gram-negative microorganisms Bacteroides caccaeBacteroides fragilisBacteroides ovatusBacteroides stercorisBacteroides thetaiotaomicronBacteroides uniformisBacteroides vulgatusCitrobacter freundiiEnterobacter cloacaeEscherichia coliFusobacterium nucleatumKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniaeParabacteroides distasonis, and Pseudomonas aeruginosa.

The FDA designated the drug combination a qualified infectious disease product, a designation given to antibacterial and antifungal drugs used in the treatment of serious or potentially fatal infections under the Generating Antibiotic Incentives Now title of the FDA Safety and Innovation Act. The drug product was also given priority review.

The FDA said in the news release that “addressing the threat of antimicrobial-resistant infections” is a “key global challenge” the agency must face. In addition, the FDA is working to facilitate the development of safe and effective new treatments for serious infections.

“The FDA remains focused on facilitating the development of safe and effective new antibacterial drugs to give patients more options to fight serious infections,” Ed Cox, MD, MPH, director for the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in the release. “It is important that the use of Recarbrio be reserved for situations when there are limited or no alternative antibacterial drugs for treating a patient’s infection.”

-GDMeds, an India Pharmacy Service company
 [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作,需遵守第三方的版权,特别是标示为第三方内容的。如用户发现侵犯版权的行为,请通知极得美。一旦收到违反通知,极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.